Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kenvue Inc. Common Stock (KVUE) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Kenvue Inc. Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Kenvue Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Kenvue Inc. Common Stock trades at $18.12 (market cap $34.11B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Kenvue Inc. Common Stock is far larger — about 18.9× Vir Biotechnology Inc. Common Stock's market cap, and Kenvue Inc. Common Stock pays a 4.73% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kenvue Inc. Common Stock for 1 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

KVUEVIR
Market Cap
$34.11B$1.80B
Volume
27,388,8111,782,836
Sector
Consumer StaplesHealth
52-Week High
$19.83$11.78
52-Week Low
$14.11$5.12
Typical Hold Time
1 Days0 Days
Enterprise Value
$41.62B$1.36B
Dividend Yield
4.73%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kenvue Inc. Common Stock

Kenvue (KVUE) trades at $17.76, down 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $15.12B in 2025, with a net income margin of 10.76% and a P/E ratio of 20.89. Recent news highlights conditional EU approval for Kimberly-Clark's $40B acquisition of Kenvue, potentially impacting future operations and shareholder returns.

The outlook is mixed, with strong profitability and consistent dividend payments offering stability, but the pending acquisition introduces uncertainty. Risks include integration challenges and market volatility. Analyst consensus is a Hold with a $19.50 price target, suggesting limited near-term upside from current levels.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KVUE

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Kenvue Inc. Common Stock

Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.

Read more on KVUE →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →